XASX
UBI
Market cap2mUSD
Aug 19, Last price
0.01AUD
Name
Universal Biosensors Inc
Chart & Performance
P/E
—
P/S
0.66
EPS
—
Div Yield, %
—
Shrs. gr., 5y
8.78%
Rev. gr., 5y
-1.85%
Revenues
6m
-5.28%
Net income
-14m
L+111.22%
CFO
-12m
L-15.86%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 2001 and headquartered in Rowville, Australia, Universal Biosensors, Inc., through its subsidiary Universal Biosensors Pty Ltd, operates as a specialized biosensor technology company. Its core business involves the creation, production, and market introduction of point-of-use devices designed to measure analytes across diverse industries. Within the medical field, the company manufactures and provides Prothrombin Time International Normalized Ratio coagulation test strips, and also acts as a distributor for Siemens' Xprecia Stride Coagulation Analyzer, which is crucial for monitoring individuals undergoing warfarin anticoagulant treatment. For the winemaking sector, UBI produces and distributes Sentia SO2 test strips and supplies the Sentia Analyzer, essential for determining free sulfur dioxide levels in post-fermentation wine. Additionally, the company offers non-diagnostic laboratory services and conducts specific coagulation testing. A key collaboration includes a licensing agreement with LifeScan Global Corporation to develop a biosensor strip and an accompanying meter for detecting and managing diabetes in animals.
IPO date
Dec 13, 2006
Employees
83
Domiciled in
AU
Incorporated in
US
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||